{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:58:30Z","timestamp":1792166310187,"version":"4.4.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Allogeneic natural killer (NK) cell immunotherapy is recognized as a promising anti-tumor strategy, but whether it plays a role in poor CD4 recovery among human immunodeficiency virus type 1 (HIV-1) infected patients is unknown. This study aimed to investigate the safety and effectiveness of allogeneic NK cells immunotherapy on HIV-1 immunological non-responders (INRs) receiving antiretroviral therapy (ART).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>From February to April 2018, a prospective, randomized, controlled, open-label clinical trial, which enrolled 20 HIV-1 INRs following specific inclusion criteria, was conducted at Nankai University Second People's Hospital. Participants were randomly allocated (simple randomization 1:1) to either the combined treatment (NK + ART) group (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a10) or the control (ART) group (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a10). The allogenic highly activated NK cells from killer cell immunoglobulin-like receptor (KIR)\/human leukocyte antigen (HLA)-<jats:italic toggle=\"yes\">Cw<\/jats:italic> mismatched healthy donor were prepared (10<jats:sup>8<\/jats:sup> cells in each injection) and intravenously infused to each recruited patient of NK+ART group in three courses. Key immune parameters (CD4 count, CD8 count, CD4\/CD8 ratio), laboratory tests (count of blood cells, biochemistry panel) and symptoms at baseline and at month 1, 3, 6, 9, 12, and 24 were measured\/collected to analyze the safety and efficacy of the therapy. Comparisons were between the seven time-points of both groups using repeated measurement analysis of variance (ANOVA) test. Generalized estimating equations (GEE) model was performed to evaluate the overall effect of the NK+ART group <jats:italic toggle=\"yes\">vs.<\/jats:italic> the ART group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>From baseline to 24 months, we noted a mean CD4 count augmentation (139 to 243 cells\/\u03bcL) in the NK + ART group and (144 to 176 cells\/\u03bcL) in the ART group (difference, 67; 95% CI, 10 to 124; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.024). Our estimations revealed that NK+ART group could improve CD4 level (<jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\u200a=\u200a54.59, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.006) and CD8 level (<jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\u200a=\u200a322.47, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.010) on average among the six measurements compared with the ART group. Only two (2\/10, 20%) participants in the NK+ART group developed a transient mild fever after the first course.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This preliminary study informs that HIV-1 INRs, allogenic NK cells immunotherapy is safe and could significantly improve CD4 recovery but not CD4\/CD8 ratio. The practical effects, however, need long-term follow-up observations. Further study on the potential underlying mechanism is warranted.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Registration info:<\/jats:title>\n            <jats:p>\n                                 www.chictr.org.cn\/showproj.aspx?proj=34912 (No. ChiCTR1900020634).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000001189","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T05:01:51Z","timestamp":1604638911000},"page":"2803-2807","source":"Crossref","is-referenced-by-count":4,"title":["Safety and efficacy of allogeneic natural killer cell immunotherapy on human immunodeficiency virus type 1 immunological non-responders: a brief report"],"prefix":"10.1097","volume":"133","author":[{"given":"Huan","family":"Xia","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Nankai University Second People's Hospital, Tianjin 300192, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Public Health Clinical Center of Chengdu, Chengdu, Sichuan 610066, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Li","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ying","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nankai University Second People's Hospital, Tianjin 300192, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cao","sequence":"additional","affiliation":[{"name":"Tianjin Institute of Hepatology, Nankai University Second People's Hospital, Tianjin 300192, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvere D.","family":"Zaongo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nankai University Second People's Hospital, Tianjin 300192, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Nan","family":"Zeng","sequence":"additional","affiliation":[{"name":"Tianjin Institute of Hepatology, Nankai University Second People's Hospital, Tianjin 300192, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"HANK Bioengineering Co., Ltd., Shenzhen, Guangdong 518000, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nankai University Second People's Hospital, Tianjin 300192, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,5]]},"reference":[{"key":"R1-20231219","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/JLB.4MR1019-189R","article-title":"Incomplete immune reconstitution in HIV\/AIDS patients on antiretroviral therapy: Challenges of immunological non-responders","volume":"107","author":"Yang","year":"2020","journal-title":"J Leukoc Biol"},{"key":"R2-20231219","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/QAD.0b013e328339cf40","article-title":"Skewed T-cell maturation and function in HIV-infected patients failing CD4+ recovery upon long-term virologically suppressive HAART","volume":"24","author":"Marchetti","year":"2010","journal-title":"AIDS"},{"key":"R3-20231219","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/QAI.0000000000000173","article-title":"Regulatory T cells in HIV-infected immunological nonresponders are increased in blood but depleted in lymphoid tissue and predict immunological reconstitution","volume":"66","author":"Gaardbo","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R4-20231219","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3389\/fimmu.2019.01205","article-title":"Cancer immunotherapy based on natural killer cells: current progress and new opportunities","volume":"10","author":"Hu","year":"2019","journal-title":"Front Immunol"},{"key":"R5-20231219","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00262-020-02532-9","article-title":"Current progress in NK cell biology and NK cell-based cancer immunotherapy","volume":"69","author":"Tarazona","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"R6-20231219","doi-asserted-by":"crossref","first-page":"7345","DOI":"10.2147\/OTT.S166962","article-title":"Iodine-125 seed implantation and allogenic natural killer cell immunotherapy for hepatocellular carcinoma after liver transplantation: a case report","volume":"11","author":"Xie","year":"2018","journal-title":"Onco Targets Ther"},{"key":"R7-20231219","doi-asserted-by":"crossref","first-page":"644","DOI":"10.4049\/jimmunol.172.1.644","article-title":"Determinants of antileukemia effects of allogeneic NK cells","volume":"172","author":"Leung","year":"2004","journal-title":"J Immunol"},{"key":"R9-20231219","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12937-015-0072-6","article-title":"Vitamin D3 supplementation in HIV infection: effectiveness and associations with antiretroviral therapy","volume":"14","author":"Coelho","year":"2015","journal-title":"Nutr J"},{"key":"R10-20231219","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/QAD.0000000000001668","article-title":"Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens","volume":"32","author":"Edwards","year":"2018","journal-title":"AIDS"},{"key":"R11-20231219","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/14787210.2017.1250624","article-title":"Strategies to limit immune-activation in HIV patients","volume":"15","author":"Bandera","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R12-20231219","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.4110\/in.2020.20.e14","article-title":"NK cell-based immunotherapies in cancer","volume":"20","author":"Shin","year":"2020","journal-title":"Immune Netw"},{"key":"R13-20231219","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/infdis\/jiu669","article-title":"Course and clinical significance of CD8+ T-Cell counts in a large cohort of HIV-Infected individuals","volume":"211","author":"Helleberg","year":"2015","journal-title":"J Infect Dis"},{"key":"R14-20231219","doi-asserted-by":"crossref","first-page":"e1006624","DOI":"10.1371\/journal.ppat.1006624","article-title":"Imbalance in the game of T cells: what can the CD4\/CD8 T-cell ratio tell us about HIV and health?","volume":"13","author":"McBride","year":"2017","journal-title":"PLoS Pathog"},{"key":"R15-20231219","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/jac\/dks533","article-title":"Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts","volume":"68","author":"Hocqueloux","year":"2013","journal-title":"J Antimicrob Chemother"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T16:09:24Z","timestamp":1703002164000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,4]]},"references-count":14,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000001189","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,4]]}}}